Compare Nucor Corporation (NUE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Repligen Corporation Common Stock — how do they compare? Nucor Corporation trades at $257.14 (market cap $57.58B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Nucor Corporation is far larger — about 5.2× Repligen Corporation Common Stock's market cap, and Nucor Corporation pays a 0.88% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Repligen Corporation Common Stock for 0 Days on average.
| NUE | RGEN | |
|---|---|---|
Market Cap | $57.58B | $11.14B |
Volume | 874,073 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $194.57 |
52-Week Low | $131.78 | $102.87 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $61.99B | $11.02B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $257.11, up 2.1% today, showing strong momentum with a 50% gain over six months. The stock is in a bullish technical trend, supported by recent earnings beats in Q1 and Q2 2026. Fundamentals reflect solid profitability with a 7.99% net margin and 13.52% ROE, though revenue has moderated from 2022 peaks. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% and recently declared its 214th consecutive dividend.
Outlook remains positive with analyst consensus at 'Buy' and a $266.88 price target, though near-term risks include competitive pressures from new steel capacity and volatility in steel prices. Earnings growth and operational efficiency are key catalysts, but investors should monitor Q3 2026 results against expectations of $5.80 EPS.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
